Gandhi, Sonia

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Ng, K. W., Faulkner, N., Cornish, G. H., Rosa, A., Harvey, R., Hussain, S., Ulferts, R., Earl, C., Wrobel, A. G., Benton, D. J., et al. (2020) · Science

SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing

Cited by 886

A common LRRK2 mutation in idiopathic Parkinson's disease

Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 774

PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death

Gandhi, S., Wood-Kaczmar, A., Yao, Z., Plun-Favreau, H., Deas, E., Klupsch, K., Downward, J., Latchman, D. S., Tabrizi, S. J., Wood, N. W., et al. (2009) · Molecular Cell

Parkinson's Disease Mechanisms and TreatmentsMitochondrial Function and Pathology

Cited by 682

α-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson’s disease

Ludtmann, M. H. R., Angelova, P. R., Horrocks, M. H., Choi, M. L., Rodrigues, M., Baev, A. Y., Berezhnov, A. V., Yao, Z., Little, D., Banushi, B., et al. (2018) · Nature Communications

Parkinson's Disease Mechanisms and TreatmentsMitochondrial Function and Pathology

Cited by 513

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Wall, E. C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., et al. (2021) · The Lancet

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 491

PINK1 protein in normal human brain and Parkinson's disease

Gandhi, S. (2006) · Brain

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 342

PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons

Wood-Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A. S. Y., Miljan, E. A., Keen, G., Stanyer, L., Hargreaves, I., Klupsch, K., Deas, E., et al. (2008) · PLoS ONE

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 316

Molecular pathogenesis of Parkinson's disease

Gandhi, S., & Wood, N. W. (2005) · Human Molecular Genetics

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 251

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., et al. (2025) · The Lancet

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 181

Progressive Motor Neuron Pathology and the Role of Astrocytes in a Human Stem Cell Model of VCP-Related ALS

Hall, C. E., Yao, Z., Choi, M., Tyzack, G. E., Serio, A., Luisier, R., Harley, J., Preza, E., Arber, C., Crisp, S. J., et al. (2017) · Cell Reports

Amyotrophic Lateral Sclerosis ResearchPluripotent Stem Cells Research

Cited by 179

Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson’s disease pathogenesis

Hughes, C. D., Choi, M. L., Ryten, M., Hopkins, L., Drews, A., Botía, J. A., Iljina, M., Rodrigues, M., Gagliano, S. A., Gandhi, S., et al. (2019) · Acta Neuropathologica

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 177

The Impact of Type 2 Diabetes in Parkinson's Disease

Athauda, D., Evans, J., Wernick, A., Virdi, G., Choi, M. L., Lawton, M., Vijiaratnam, N., Girges, C., Ben‐Shlomo, Y., Ismail, K., et al. (2022) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 132

Beta amyloid aggregates induce sensitised TLR4 signalling causing long-term potentiation deficit and rat neuronal cell death

Hughes, C., Choi, M. L., Yi, J.-H., Kim, S.-C., Drews, A., George-Hyslop, P. S., Bryant, C., Gandhi, S., Cho, K., & Klenerman, D. (2020) · Communications Biology

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 107

Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains

Faulkner, N., Ng, K. W., Wu, M. Y., Harvey, R., Margaritis, M., Paraskevopoulou, S., Houlihan, C., Hussain, S., Greco, M., Bolland, W., et al. (2021) · eLife

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 52

The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1

Gustavsson, E. K., Sethi, S., Gao, Y., Brenton, J. W., García-Ruiz, S., Zhang, D., Garza, R., Reynolds, R. H., Evans, J. R., Chen, Z., et al. (2024) · Science Advances

Lysosomal Storage Disorders ResearchGenomics and Phylogenetic Studies

Cited by 30